Best practice & research. Clinical rheumatologyHumansAxial SpondyloarthritisInterleukin-17AntibodiesMonoclonal
Novel therapies for axial spondyloarthritis and future directions.
Marta Dzhus, Walter P Maksymowych
Published: 202510.1016/j.berh.2025.102105
Abstract
This update explores emerging therapeutic strategies aimed at novel targets implicated in the pathogenesis of axSpA. Recent clinical trials of bimekizumab, a monoclonal antibody targeting both IL-17A and IL-17F, and janus-kinase inhibitors have demon…
Preview only. Read the full abstract at the source